97 related articles for article (PubMed ID: 7742159)
1. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan.
Persson K; Sjöström S; Sigurdardottir I; Molnár V; Hammarlund-Udenaes M; Rane A
Br J Clin Pharmacol; 1995 Feb; 39(2):182-6. PubMed ID: 7742159
[TBL] [Abstract][Full Text] [Related]
2. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1.
Mortimer O; Persson K; Ladona MG; Spalding D; Zanger UM; Meyer UA; Rane A
Clin Pharmacol Ther; 1990 Jan; 47(1):27-35. PubMed ID: 2295216
[TBL] [Abstract][Full Text] [Related]
5. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake.
Sindrup SH; Hofmann U; Asmussen J; Mikus G; Brøsen K; Nielsen F; Ingwersen SH; Broen Christensen C
Eur J Clin Pharmacol; 1996; 49(6):503-9. PubMed ID: 8706777
[TBL] [Abstract][Full Text] [Related]
6. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
7. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype.
Stamer UM; Stüber F
Anaesthesia; 2007 Dec; 62(12):1294-5; author reply 1295-6. PubMed ID: 17991273
[No Abstract] [Full Text] [Related]
8. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P
J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P4502D6 genotype does not determine response to clozapine.
Arranz MJ; Dawson E; Shaikh S; Sham P; Sharma T; Aitchison K; Crocq MA; Gill M; Kerwin R; Collier DA
Br J Clin Pharmacol; 1995 Apr; 39(4):417-20. PubMed ID: 7640149
[TBL] [Abstract][Full Text] [Related]
10. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
Sindrup SH; Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF
Pain; 1993 Jun; 53(3):335-339. PubMed ID: 8351162
[TBL] [Abstract][Full Text] [Related]
11. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
12. Codeine intoxication associated with ultrarapid CYP2D6 metabolism.
Gasche Y; Daali Y; Fathi M; Chiappe A; Cottini S; Dayer P; Desmeules J
N Engl J Med; 2004 Dec; 351(27):2827-31. PubMed ID: 15625333
[TBL] [Abstract][Full Text] [Related]
13. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
Lötsch J; Rohrbacher M; Schmidt H; Doehring A; Brockmöller J; Geisslinger G
Pain; 2009 Jul; 144(1-2):119-24. PubMed ID: 19395173
[TBL] [Abstract][Full Text] [Related]
14. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
15. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
Zimmermann T; Schlenk R; Pfaff G; Lach P; Wildfeuer A
Arzneimittelforschung; 1995 Jan; 45(1):41-3. PubMed ID: 7893267
[TBL] [Abstract][Full Text] [Related]
16. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.
Kerry NL; Somogyi AA; Bochner F; Mikus G
Br J Clin Pharmacol; 1994 Sep; 38(3):243-8. PubMed ID: 7826826
[TBL] [Abstract][Full Text] [Related]
17. A Single Site Population Study to Investigate CYP2D6 Phenotype of Patients with Persistent Non-Malignant Pain.
Radford H; Simpson KH; Rogerson S; Johnson MI
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31141989
[No Abstract] [Full Text] [Related]
18. Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man.
Ladona MG; Lindström B; Thyr C; Dun-Ren P; Rane A
Br J Clin Pharmacol; 1991 Sep; 32(3):295-302. PubMed ID: 1838002
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
20. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers.
Chen ZR; Somogyi AA; Reynolds G; Bochner F
Br J Clin Pharmacol; 1991 Apr; 31(4):381-90. PubMed ID: 2049245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
